
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
Immunome is seeking an experienced and strategic Director / Senior Director, US Market Access to develop and execute the US market access strategy for our oncology portfolio. This role will lead payer and channel strategy for varegacestat from pre-launch through launch, overseeing payer marketing materials, pricing, value proposition development, and contracting, while also helping shape U.S. market access strategy for pipeline assets as they advance into late-stage development.
The successful candidate will bring deep expertise in the US payer landscape and specialty access pathways, along with a proven track record executing market access plans that maximize patient access. This role will partner closely with HEOR, Distribution/Trade, and field teams to deliver coverage, pull-through, and patient access solutions.
Responsibilities
Strategic Market Access Leadership
Value Proposition, Evidence and Payer Marketing Materials
Pricing Strategy and Contracting
Channel, Distribution and Patient Access Operations
Leadership and Collaboration
Qualifications
Knowledge and Skills
Washington State Pay Range $236,650—$320,791 USD
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.